apolipoproteins b

Summary

Summary: Structural proteins of chylomicrons, VLDL; and LDL. They are important in the secretion and transport of these LIPOPROTEINS and function as recognition signals for binding and internalization of LDL particles by the LDL receptor (RECEPTORS, LDL). Atherosclerotic patients show high levels of Apo-B in the blood while in the case of ABETALIPOPROTEINEMIA they are not detectable in serum.

Top Publications

  1. ncbi Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion
    Pablo Gastaminza
    The Scripps Research Institute, Maildrop SBR 10, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    J Virol 82:2120-9. 2008
  2. ncbi Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins
    Hua Huang
    Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390 9046, USA
    Proc Natl Acad Sci U S A 104:5848-53. 2007
  3. ncbi Can measurement of serum apolipoprotein B replace the lipid profile monitoring of patients with lipoprotein disorders?
    Saman Miremadi
    Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, V6Z 1Y6, Canada
    Clin Chem 48:484-8. 2002
  4. ncbi Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study
    B H R Wolffenbuttel
    University Medical Centre, Groningen, The Netherlands
    J Intern Med 257:531-9. 2005
  5. ncbi Nascent lipidated apolipoprotein B is transported to the Golgi as an incompletely folded intermediate as probed by its association with network of endoplasmic reticulum molecular chaperones, GRP94, ERp72, BiP, calreticulin, and cyclophilin B
    Jianying Zhang
    Department of Physiology and Biophysics, Center for Advanced Biomedical Research, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    J Biol Chem 278:7459-68. 2003
  6. ncbi RNAi-mediated gene silencing in non-human primates
    Tracy S Zimmermann
    Alnylam Pharmaceuticals Inc, 300 Third Street, Cambridge, Massachusetts 02142, USA
    Nature 441:111-4. 2006
  7. ncbi Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Montreal, , Canada
    Am J Cardiol 91:1173-7. 2003
  8. ncbi Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome
    Robert S Rosenson
    Division of Cardiovascular Medicine, University of Michigan, Domino s Farms, 24 Frank Lloyd Wright Dr, Lobby A, Ann Arbor, MI 48106 0736, USA
    Diabetes Care 30:1945-51. 2007
  9. ncbi Impaired recycling of apolipoprotein E4 is associated with intracellular cholesterol accumulation
    Joerg Heeren
    Institute for Biochemistry and Molecular Biology II Molecular Cell Biology and Department of Internal Medicine, University Hospital Eppendorf, Martinistrasse 52, D 20246 Hamburg, Germany
    J Biol Chem 279:55483-92. 2004
  10. ncbi Intracellular assembly of VLDL: two major steps in separate cell compartments
    S O Olofsson
    Department of Medical Biochemistry and the Wallenberg Laboratory for Cardiovascular Research, University of Goteborg, Goteborg, Sweden Sven Olof
    Trends Cardiovasc Med 10:338-45. 2000

Research Grants

  1. Development of CNS-targeted AAV vectors
    Miguel Esteves; Fiscal Year: 2009
  2. APOLIPOPROTEIN B48 AND LIPOPROTEIN METABOLISM
    Lawrence Chan; Fiscal Year: 2004
  3. ASSEMBLY PATHWAY OF VLDL--A THREE STEP PROCESS
    LARRY SWIFT; Fiscal Year: 2001
  4. ApoB and ApoA-I Kinetics in the ApoB-67 Mutation
    Francine Welty; Fiscal Year: 2006
  5. REGULATION OF APOB SECRETION IN INBRED MOUSE STRAINS
    Li Shin Huang; Fiscal Year: 2009
  6. INTESTINAL LIPOPROTEINS IN THE NEONATE
    Dennis Black; Fiscal Year: 2001
  7. LIPOGENESIS & LIPOPROTEIN COMPLICATIONS OF HIV THERAPY
    David Hui; Fiscal Year: 2004
  8. EDITING OF APOLIPOPROTEIN-B MRNA
    DONNA DRISCOLL; Fiscal Year: 2004
  9. APOLIPOPROTEIN B48 AND LIPOPROTEIN METABOLISM
    Lawrence Chan; Fiscal Year: 1999
  10. METABOLISM AND GENETICS OF HYPOBETALIPOPROTEINEMIA
    Gustav Schonfeld; Fiscal Year: 2002

Detail Information

Publications187 found, 100 shown here

  1. ncbi Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion
    Pablo Gastaminza
    The Scripps Research Institute, Maildrop SBR 10, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    J Virol 82:2120-9. 2008
    ..These results suggest that by coopting the VLDL assembly, maturation, degradation, and secretory machinery of the cell, HCV acquires its hepatocyte tropism and, by mimicry, its tendency to persist...
  2. ncbi Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins
    Hua Huang
    Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390 9046, USA
    Proc Natl Acad Sci U S A 104:5848-53. 2007
    ..These results provide a possible explanation for the restriction of HCV production to the liver and suggest new cellular targets for treatment of HCV infection...
  3. ncbi Can measurement of serum apolipoprotein B replace the lipid profile monitoring of patients with lipoprotein disorders?
    Saman Miremadi
    Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, V6Z 1Y6, Canada
    Clin Chem 48:484-8. 2002
    ..Considerable evidence indicates that apolipoprotein B (apo B) is a better index of reaching or not reaching treatment targets than total or LDL cholesterol...
  4. ncbi Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study
    B H R Wolffenbuttel
    University Medical Centre, Groningen, The Netherlands
    J Intern Med 257:531-9. 2005
    ..To compare the efficacy of the newest cholesterol-lowering drug, rosuvastatin (RSV) with atorvastatin (ATV) in subjects with type 2 diabetes...
  5. ncbi Nascent lipidated apolipoprotein B is transported to the Golgi as an incompletely folded intermediate as probed by its association with network of endoplasmic reticulum molecular chaperones, GRP94, ERp72, BiP, calreticulin, and cyclophilin B
    Jianying Zhang
    Department of Physiology and Biophysics, Center for Advanced Biomedical Research, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    J Biol Chem 278:7459-68. 2003
    ....
  6. ncbi RNAi-mediated gene silencing in non-human primates
    Tracy S Zimmermann
    Alnylam Pharmaceuticals Inc, 300 Third Street, Cambridge, Massachusetts 02142, USA
    Nature 441:111-4. 2006
    ..Our findings show clinically relevant RNAi-mediated gene silencing in non-human primates, supporting RNAi therapeutics as a potential new class of drugs...
  7. ncbi Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Montreal, , Canada
    Am J Cardiol 91:1173-7. 2003
    ....
  8. ncbi Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome
    Robert S Rosenson
    Division of Cardiovascular Medicine, University of Michigan, Domino s Farms, 24 Frank Lloyd Wright Dr, Lobby A, Ann Arbor, MI 48106 0736, USA
    Diabetes Care 30:1945-51. 2007
    ..The aim of this study was to determine the effects of fenofibrate (160 mg/day) on fasting and postprandial lipoproteins, oxidized fatty acids, and inflammatory mediators in subjects with hypertriglyceridemia and the metabolic syndrome...
  9. ncbi Impaired recycling of apolipoprotein E4 is associated with intracellular cholesterol accumulation
    Joerg Heeren
    Institute for Biochemistry and Molecular Biology II Molecular Cell Biology and Department of Internal Medicine, University Hospital Eppendorf, Martinistrasse 52, D 20246 Hamburg, Germany
    J Biol Chem 279:55483-92. 2004
    ..These studies provide initial evidence that impaired recycling of apoE4 could interfere with intracellular cholesterol transport and contribute to the pathophysiological lipoprotein profile observed in apoE4 homozygotes...
  10. ncbi Intracellular assembly of VLDL: two major steps in separate cell compartments
    S O Olofsson
    Department of Medical Biochemistry and the Wallenberg Laboratory for Cardiovascular Research, University of Goteborg, Goteborg, Sweden Sven Olof
    Trends Cardiovasc Med 10:338-45. 2000
    ..In the second step pre-VLDL is converted to bona fide VLDL in a smooth membrane compartment. This step depends on ADP-ribosylation factor 1 and its activation of phospholipase D...
  11. ncbi ApoB/ApoA1 ratio and subclinical atherosclerosis
    A Panayiotou
    Department of Biomedical Sciences, University of Cyprus, Nicosia, Cyprus
    Int Angiol 27:74-80. 2008
    ..The aim of this study was to test the hypothesis that ApoB/ApoA1 ratio is associated with early subclinical atherosclerosis as demonstrated by ultrasonic measurements...
  12. ncbi A population-based, cross-sectional comparison of lipid-related indexes for symptoms of atherosclerotic disease
    Stanley H Hsia
    Division of Endocrinology, Metabolism and Molecular Medicine, Charles R Drew University of Medicine and Science, Los Angeles, California, USA
    Am J Cardiol 98:1047-52. 2006
    ..The LDL/HDL cholesterol ratio was only significant for lean patients. In conclusion, these observations add to the published data suggesting that LDL cholesterol may not be the best target of lipid-lowering treatment strategies...
  13. ncbi Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy
    G Walldius
    King Gustaf V Research Institute and Karolinska Institute, Stockholm, Sweden
    J Intern Med 255:188-205. 2004
    ..Measurement of these apolipoproteins could improve cardiovascular risk prediction...
  14. ncbi Inhibition of net HepG2 cell apolipoprotein B secretion by the citrus flavonoid naringenin involves activation of phosphatidylinositol 3-kinase, independent of insulin receptor substrate-1 phosphorylation
    Nica M Borradaile
    Department of Medicine and the Robarts Research Institute, University of Western Ontario, London, Ontario, Canada
    Diabetes 52:2554-61. 2003
    ..Although this pathway may not regulate apoB secretion in primary hepatocytes, PI3K activation by this novel mechanism may explain the insulin-like effects of naringenin in vivo...
  15. ncbi Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients
    Søren U Nielsen
    Liver Research Group, School of Clinical Medical Sciences, University of Newcastle, England
    J Virol 80:2418-28. 2006
    ..Immunoprecipitation analysis showed that ApoB remained associated with HCV after treatment of serum with deoxycholic acid or NP-40, whereas ApoE was removed from HCV with these detergents...
  16. ncbi High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study
    G Walldius
    Astra Zeneca, Mölndal and King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden
    Lancet 358:2026-33. 2001
    ..We also aimed to establish whether apoB and apoA-I add further information about risk of fatal myocardial infarction to that obtained with total cholesterol, triglycerides, and LDL-cholesterol...
  17. ncbi Oxidation of apolipoprotein B-containing lipoproteins and serum paraoxonase/arylesterase activities in major depressive disorder
    Asli Sarandol
    Department of Psychiatry, Uludag University Medical Faculty, 16059 Bursa, Turkey
    Prog Neuropsychopharmacol Biol Psychiatry 30:1103-8. 2006
    ..The findings of the present study suggest that: 1) antidepressant treatment might reduce serum paraoxonase activity/mass; 2) oxidation and oxidizability of apolipoprotein B-containing lipoproteins seem to be increased in MDD...
  18. ncbi Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
    Jürgen Soutschek
    Alnylam Europe AG, Fritz Hornschuch Str 9, 95326 Kulmbach, Germany
    Nature 432:173-8. 2004
    ..These findings demonstrate the therapeutic potential of siRNAs for the treatment of disease...
  19. ncbi MicroRNA-like off-target transcript regulation by siRNAs is species specific
    Julja Burchard
    Rosetta Inpharmatics LLC, Seattle, Washington 98109, USA
    RNA 15:308-15. 2009
    ..Therefore, siRNA therapeutics may trigger microRNA-like silencing of many unintended targets in vivo, and the potential toxicities caused by these off-target gene regulations cannot be accurately assessed in rodent models...
  20. ncbi The 9cis,11trans,13cis isomer of conjugated linolenic acid reduces apolipoprotein B100 secretion and triacylglycerol synthesis in HepG2 cells
    Keisuke Arao
    Department of Applied Biological Sciences, Saga University, Honjyo-1, Saga 840-8502, Japan
    Biosci Biotechnol Biochem 68:2643-5. 2004
    ..The uptake of (14)C-oleate into newly synthesized cellular triacylglycerol was also decreased by 9c,11t,13c-CLNA more than by alpha-LNA treatment. This is the first study to show the hypolipidemic effect of 9c,11t,13c-CLNA...
  21. ncbi Clinical utility of different lipid measures for prediction of coronary heart disease in men and women
    Erik Ingelsson
    Framingham Heart Study, 73 Mount Wayte Ave, Suite 2, Framingham, MA 01702 5803
    JAMA 298:776-85. 2007
    ..Evidence is conflicting regarding the performance of apolipoproteins vs traditional lipids for predicting coronary heart disease (CHD) risk...
  22. ncbi APOLIPOPROTEIN B: mRNA editing, lipoprotein assembly, and presecretory degradation
    N O Davidson
    Departments of Medicine and Molecular Biology and Pharmacology, Washington University Medical School, St Louis, Missouri 63110, USA
    Annu Rev Nutr 20:169-93. 2000
    ..Although control of lipid secretion in vivo is primarily achieved at the level of lipoprotein particle size, regulation of apoB production by presecretory degradation may be relevant in some dyslipidemic states...
  23. ncbi Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study
    A R Sharrett
    Epidemiology and Biometry Program, National Heart, Lung, and Blood Institute, Bethesda, MD, USA
    Circulation 104:1108-13. 2001
    ..CONCLUSIONS: Optimal LDL-C values are <100 mg/dL in both women and men. LDL-C, HDL-C, TG, and Lp(a), without additional apolipoproteins or lipid subfractions, provide substantial CHD prediction, with much higher RR in women than men...
  24. ncbi Subendothelial retention of atherogenic lipoproteins in early atherosclerosis
    Kristina Skålén
    Wallenberg Laboratory for Cardiovascular Research, Goteborg University, Göteborg S 4345, Sweden
    Nature 417:750-4. 2002
    ..We conclude that subendothelial retention of apoB100-containing lipoprotein is an early step in atherogenesis...
  25. ncbi Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B
    John J P Kastelein
    Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, PO Box 22700, Room F4 159 2, 1100 DE Amsterdam, The Netherlands
    Circulation 114:1729-35. 2006
    ..In the present study, we describe the outcome of the first-in-humans study on the safety and efficacy of an antisense oligonucleotide inhibitor of apoB...
  26. ncbi Familial defective apolipoprotein B and familial hypobetalipoproteinemia in one family: two neutralizing mutations
    Anouk van der Graaf
    Ann Intern Med 148:712-4. 2008
  27. ncbi The paraoxonase gene polymorphism in stroke patients and lipid profile
    B S Shin
    Department of Neurology, Chonbuk National University Hospital and Medical School, Keumamdong, Jeonju, Chonbuk, Republic of Korea
    Acta Neurol Scand 117:237-43. 2008
    ..We investigated the associations between PON polymorphisms and ischemic stroke. We also investigated the associations between PON polymorphisms and lipid profile in stroke patients...
  28. ncbi Polymorphisms in the apolipoprotein B-100 gene: association with plasma lipid concentration and coronary artery disease
    Ratna Dua Puri
    Department of Medical Genetics, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow
    Indian Heart J 55:60-4. 2003
    ..The aim of this study was to investigate the association of apolipoprotein B gene polymorphisms with coronary artery disease and lipid levels in Indians...
  29. ncbi Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly
    M Mahmood Hussain
    Department of Anatomy, SUNY Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, NY 11203, USA
    J Lipid Res 44:22-32. 2003
    ..However, specific steps in lipoprotein assembly that require apoB-MTP binding have not been identified. ApoB-MTP binding may be important for the prevention of degradation and lipidation of nascent apoB...
  30. ncbi Short-term overexpression of DGAT1 or DGAT2 increases hepatic triglyceride but not VLDL triglyceride or apoB production
    John S Millar
    Department of Pharmacology, University of Pennsylvania, Philadelphia, PA, USA
    J Lipid Res 47:2297-305. 2006
    ..In the presence of adequate cytoplasmic lipid stores, factors other than triglyceride synthesis are rate-limiting for VLDL production...
  31. ncbi Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy
    Scott M Grundy
    Circulation 106:2526-9. 2002
  32. ncbi Childhood levels of serum apolipoproteins B and A-I predict carotid intima-media thickness and brachial endothelial function in adulthood: the cardiovascular risk in young Finns study
    Markus Juonala
    Department of Medicine, University of Turku, Turku, Finland
    J Am Coll Cardiol 52:293-9. 2008
    ..The aim of this study was to determine whether apolipoproteins (apo) B and A-I measured in childhood and adolescence predict atherosclerosis in adulthood...
  33. ncbi ApoC-III gene polymorphisms and risk of coronary artery disease
    Oliviero Olivieri
    Unit of Internal Medicine, Institute of Clinical Chemistry, University of Verona, Verona, Italy
    J Lipid Res 43:1450-7. 2002
    ..5 and 2.18 for unadjusted and adjusted models, respectively) suggesting that it represents an independent genetic susceptibility factor for CAD...
  34. ncbi Apo-B/apo-AI ratio: a better discriminator of coronary artery disease risk than other conventional lipid ratios in Indian patients with acute myocardial infarction
    Binita Goswami
    Department of Biochemistry, Maulana Azad Medical College, New Delhi, India
    Acta Cardiol 63:749-55. 2008
    ....
  35. ncbi Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis
    Gabriel Perlemuter
    Liver Cancer and Molecular Virology, Institut National de la Santé et de la Recherche Médicale Unité 370, Faculte de Medecine Necker Enfants Malades, 75730 Paris Cedex 15, France
    FASEB J 16:185-94. 2002
    ....
  36. ncbi Association of C677T polymorphism in MTHFR gene, high homocysteine and low HDL cholesterol plasma values in heterozygous familial hypercholesterolemia
    Jose T Real
    Hospital Clinico Universitario, Department of Medicine, University of Valencia, Spain
    J Atheroscler Thromb 16:815-20. 2009
    ..to investigate the association of C677T polymorphism in the methylene tetrahydrofolate reductase (MTHFR) gene, homocysteine plasma values (Hcy), and plasma HDL cholesterol in heterozy-gous familial hypercholesterolemia (hFH)...
  37. ncbi Cardiac lipid accumulation associated with diastolic dysfunction in obese mice
    Christina Christoffersen
    Departments of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark 2100
    Endocrinology 144:3483-90. 2003
    ..The results also suggest that the cardiac lipid accumulation is paralleled by cardiac diastolic dysfunction in ob/ob mice...
  38. ncbi Identification of the lipoprotein initiating domain of apolipoprotein B
    Gregory S Shelness
    Department of Pathology, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157 1040, USA
    J Biol Chem 278:44702-7. 2003
    ..The composition of lipids recruited into lipoproteins by this initiating domain is consistent with formation of small emulsion particles, perhaps by simultaneous desorption of both polar and neutral lipids from a saturated bilayer...
  39. ncbi [VNTR3' polymorphism of apoliproprotein B gene in obese people]
    R Jemaa
    Laboratoire de Biochimie, Hopital La Rabta, 1007 Jabbari Tunis, Tunisie
    Ann Biol Clin (Paris) 60:559-64. 2002
    ..Our study confirms in the obese subjects, results published in the general litterature, and shows that the apoB has an important role in the metabolism of plasma lipids and most particulary its gene variants...
  40. ncbi Intestinal insulin resistance and aberrant production of apolipoprotein B48 lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia: evidence for activation of protein tyrosine phosphatase-1B, extracellular signal-related kinase,
    Lisa M Federico
    Division of Clinical Biochemistry DPLM, Hospital for Sick Children, 555 University Ave, Toronto, Ontario, Canada M5G 1X8
    Diabetes 55:1316-26. 2006
    ..Basal activation of the ERK pathway may be an important contributor to the aberrant insulin signaling and lipoprotein overproduction in this model...
  41. ncbi The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence
    G Walldius
    King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden
    J Intern Med 259:493-519. 2006
    ..Guidelines should be developed in order to recognize the important clinical risk information embedded in the apoB/apoA-I ratio...
  42. ncbi Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study
    Marianne Benn
    Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, DK 2100 Copenhagen Ø, Denmark
    Arterioscler Thromb Vasc Biol 27:661-70. 2007
    ..We tested the following hypotheses: apoB predicts ischemic cardiovascular events, and apoB is a better predictor of ischemic cardiovascular events than low-density lipoprotein cholesterol...
  43. ncbi Update of the molecular basis of familial hypercholesterolemia in The Netherlands
    Sigrid W Fouchier
    Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Hum Mutat 26:550-6. 2005
    ....
  44. ncbi Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia
    Delphine Allard
    INSERM UR383, Hopital Necker Enfants Malades
    Hum Mutat 26:497. 2005
    ..3%) and that additional environmental or genetic factors may contribute to the phenotype caused by PCSK9 missense mutations in humans...
  45. ncbi Serum lipid levels and cognitive change in late life
    Chandra A Reynolds
    Department of Psychology, University of California at Riverside, Riverside, California 92521, USA
    J Am Geriatr Soc 58:501-9. 2010
    ..To assess the effect of lipids and lipoproteins on longitudinal cognitive performance and cognitive health in late life and to consider moderating factors such as age and sex that may clarify conflicting prior evidence...
  46. ncbi Evolution and mechanism of apolipoprotein B-containing lipoprotein assembly
    Gregory S Shelness
    Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157-1040, USA
    Curr Opin Lipidol 16:325-32. 2005
    ..Some of these factors and processes may be targeted therapeutically to modulate the quantitative and qualitative aspects of apolipoprotein B production...
  47. ncbi Effect of uremia on HDL composition, vascular inflammation, and atherosclerosis in wild-type mice
    Christian A Bang
    Department of Clinical Biochemistry, University of Copenhagen, Copenhagen, Denmark
    Am J Physiol Renal Physiol 293:F1325-31. 2007
    ..The results suggest that moderate uremia neither induces aortic inflammation nor atherosclerosis in C57BL/6J mice despite increased LDL/HDL cholesterol ratio and altered HDL composition...
  48. ncbi Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study
    Naveed Sattar
    Section of Vascular Biochemistry, North Glasgow Hospitals University NHS Trust, Glasgow Royal Infirmary, Glasgow, UK
    Circulation 110:2687-93. 2004
    ..Our data suggest that apoB is a better candidate risk parameter than NHDLC for identifying a subgroup of individuals with or without MetS with elevated cardiovascular risk...
  49. ncbi Optimization of apolipoprotein B mRNA editing by APOBEC1 apoenzyme and the role of its auxiliary factor, ACF
    Ann Chester
    RNA Editing Group, MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College, Hammersmith Campus, London, UK
    RNA 10:1399-411. 2004
    ..Notably, the substantial RNA editing activity of APOBEC1 alone may be responsible for the "hyperediting" observed upon overexpression of APOBEC1 in transgenic mice...
  50. ncbi Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of low-density lipoprotein-containing human apolipoprotein B100
    Christofer Flood
    Wallenberg Laboratory for Cardiovascular Research, Sahlgrenska Academy at Goteborg University, Goteborg, Sweden
    Arterioscler Thromb Vasc Biol 24:564-70. 2004
    ....
  51. ncbi Influence of polymorphism (RFLP-sstI) at the apolipoprotein C-III gene locus on the lipoprotein metabolism and insulin resistance in essential hypertensive patients. Interaction between gender and genetic polymorphism
    A Espino-Montoro
    Investigation Unit, Department of Internal Medicine, De la Merced University Hospital, Osuna, Spain
    Nutr Metab Cardiovasc Dis 13:194-201. 2003
    ..We also examined the influence of the S1S2 allele on blood pressure and the interaction of the mutation at the apo C-III gene and the gender...
  52. ncbi Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formula
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, McGill University, Montreal, Quebec, Canada
    Clin Biochem 36:499-504. 2003
  53. ncbi Very low density lipoprotein (VLDL) receptor-deficient mice have reduced lipoprotein lipase activity. Possible causes of hypertriglyceridemia and reduced body mass with VLDL receptor deficiency
    Hiroaki Yagyu
    Department of Medicine, Columbia University, New York, New York 10032, USA
    J Biol Chem 277:10037-43. 2002
    ..Therefore, the VLDLr is required for normal LpL regulation in vivo, and the disruption of VLDLr results in hypertriglyceridemia associated with decreased LpL activity...
  54. ncbi Lack of association between the apolipoprotein B gene 3' hypervariable region alleles and coronary artery disease in Finnish patients with angiographically documented coronary artery disease
    T Helio
    First Department of Medicine, University of Helsinki, Finland
    J Intern Med 231:49-57. 1992
    ..In addition, there was no significant association between the 3'VNTR alleles and serum lipid levels in this Finnish population...
  55. ncbi Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia
    H Campos
    Department of Nutrition, Harvard School of Public Health, Boston, MA 02115, USA
    J Lipid Res 42:1239-49. 2001
    ..Therefore, VLDL particles with apoC-III may play a central role in identifying the high risk of coronary heart disease in hypertriglyceridemia, but their substantial prevalence in normolipidemics may be of clinical significance as well...
  56. ncbi Comparison of the effects of dietary n-3 and n-6 polyunsaturated fatty acids on very-low-density lipoprotein secretion when delivered to hepatocytes in chylomicron remnants
    X Zheng
    Department of Veterinary Basic Sciences, The Royal Veterinary College, Royal College St, London NW1 0TU, UK
    Biochem J 357:481-7. 2001
    ....
  57. ncbi Molecular cloning of apobec-1 complementation factor, a novel RNA-binding protein involved in the editing of apolipoprotein B mRNA
    A Mehta
    Department of Cell Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Mol Cell Biol 20:1846-54. 2000
    ..The fact that ACF is widely expressed in human tissues that lack apobec-1 and apo-B mRNA suggests that ACF may be involved in other RNA editing or RNA processing events...
  58. ncbi APO B 3' HVR polymorphism in healthy population: relationships to serum lipid levels
    D Alavantic
    Laboratory for Radiobiology and Molecular Genetics, Vinca Institute of Nuclear Sciences, Belgrade, Serbia
    Genet Epidemiol 15:113-22. 1998
    ....
  59. ncbi Apo B100-containing lipoproteins are secreted by the heart
    J Boren
    Gladstone Institute of Cardiovascular Disease, University of California, San Francisco, California 94141 9100, USA
    J Clin Invest 101:1197-202. 1998
    ..These studies reveal that the heart, and not just the liver and intestine, secretes apo B-containing lipoproteins. We speculate that lipoprotein secretion by the heart represents a mechanism for removing excess lipids from the heart...
  60. ncbi Intracellular trafficking determinants in APOBEC-1, the catalytic subunit for cytidine to uridine editing of apolipoprotein B mRNA
    Y Yang
    Department of Biochemistry and Biophysics, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    Exp Cell Res 267:153-64. 2001
    ..The findings are discussed in terms of their implications in the regulation of nuclear editing activity and the possibility that interactions with chaperones may play a role in the cellular distribution of APOBEC-1...
  61. ncbi Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100
    L F Soria
    Gladstone Foundation Laboratories for Cardiovascular Disease, University of California, San Francisco 94140 0608
    Proc Natl Acad Sci U S A 86:587-91. 1989
    ..Thus, it appears that the mutation in the codon for amino acid 3500 (CGG----CAG), a CG mutational "hot spot," defines a minor apoB-100 allele associated with defective low density lipoproteins and hypercholesterolemia...
  62. ncbi Comparison of the measurement of lipids and lipoproteins versus assay of apolipoprotein B for estimation of coronary heart disease risk: a study in familial combined hyperlipidemia
    P N Demacker
    Department of Medicine, UMC St Radboud, Nijmegen, The Netherlands
    Atherosclerosis 153:483-90. 2000
    ....
  63. ncbi The peroxisome proliferator-activated receptor alpha (PPARalpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the development of atherosclerotic lesions
    Tao Fu
    Department of Pathology, Northwestern University Feinberg School of Medicine, 303 E Chicago Avenue, Chicago, IL 60611, USA
    J Biol Chem 279:28662-9. 2004
    ..These findings demonstrate that ciprofibrate treatment decreases hepatic apoB mRNA editing and alters the pattern of hepatic lipoprotein secretion toward apoB-100-associated VLDL, changes that in turn lead to increased atherosclerosis...
  64. ncbi The expression of apolipoprotein B epitopes is normal in LDL of diabetic and end-stage renal disease patients
    S Braschi
    Endocrinology Division, Medicine Department, University of Ottawa, Ottawa Hospital, Riverside Campus, 1967 Riverside Drive, Ottawa, ON, K1H 7W9, Canada
    Diabetologia 49:1394-401. 2006
    ..The aim of this work was to determine if similar immunological changes are observed in vivo in LDLs of diabetic and end-stage renal disease (ESRD) patients...
  65. ncbi Changes in serum levels of leptin, cytokines and lipoprotein in pre-eclamptic and normotensive pregnant women
    Y Kocyigit
    Department of Physiology, School of Medicine, Dicle University, Diyarbakir, Turkey
    Gynecol Endocrinol 19:267-73. 2004
    ..These association may be due to the abnormal lipid metabolism and immune activation involved in the pathogenesis of this disease...
  66. ncbi Expression of human apolipoprotein A-II in apolipoprotein E-deficient mice induces features of familial combined hyperlipidemia
    J C Escolà-Gil
    Servei de Bioquímica de l Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain
    J Lipid Res 41:1328-38. 2000
    ..We conclude that apoE-deficient mice overexpressing human apoA-II constitute useful animal models with which to study the mechanisms leading to overproduction of VLDL, and that apoA-II may function to regulate VLDL production...
  67. ncbi Phytoestrogen alpha-zearalanol inhibits atherogenesis and improves lipid profile in ovariectomized cholesterol-fed rabbits
    Shunling Dai
    Faculty of Basic Medicine, Peking Union Medical College, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, P R China 100005
    Endocrine 25:121-9. 2004
    ..Our findings indicate that the phytoestrogen alpha-ZAL has an important anti-atherogenic property, analogous to that of estrogen...
  68. ncbi Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes
    Kaspar Berneis
    Department of Internal Medicine and Central Laboratories, Basel University Hospital Bruderholz, Switzerland 4101
    Metabolism 54:227-34. 2005
    ..002) and IMT (P = .03). It is concluded that LDL size is the strongest marker for clinically apparent as well as non-apparent atherosclerosis in diabetes type 2...
  69. ncbi [Blood lipids and lipoproteins in acute organophosphorus insecticide poisoning patients]
    Hai-yin Leu
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 21:225. 2003
  70. ncbi Abnormal lipid metabolism in cystathionine beta-synthase-deficient mice, an animal model for hyperhomocysteinemia
    Kazuhiko Namekata
    National Institute of Neuroscience, National Center of Neurology and Psychiatry, Ogawahigashi 4 1 1, Kodaira, Tokyo 187 8551, Japan
    J Biol Chem 279:52961-9. 2004
    ..Moreover, serum cholesterol/triglyceride distribution in lipoprotein fractions was altered in CBS(-/-) mice. These results suggest that hepatic steatosis in CBS(-/-) mice is caused by or associated with abnormal lipid metabolism...
  71. ncbi Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults
    Stephanie Badiou
    Laboratoire de Biochimie des Lipides, Department of Biochemistry, 371 Av du Doyen Gaston Giraud, , CHU Montpellier F34295, France
    Atherosclerosis 172:273-9. 2004
    ..CONCLUSION: Fenofibrate therapy improves the atherogenic lipid profile in HIV-positive adults with hypertriglyceridemia...
  72. ncbi Insulin resistance is independently associated with postprandial alterations of triglyceride-rich lipoproteins in type 2 diabetes mellitus
    Giovanni Annuzzi
    Department of Clinical and Experimental Medicine, Federico II University, Naples, Italy
    Arterioscler Thromb Vasc Biol 24:2397-402. 2004
    ....
  73. ncbi Lipoprotein metabolism in subjects with hepatic lipase deficiency
    Marju Tilly-Kiesi
    Helsinki University Central Hospital, Helsinki, Finland
    Metabolism 53:520-5. 2004
    ..HL deficiency may result in a lipoprotein pattern associated with low heart disease risk...
  74. ncbi Effects of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients
    Ayako Ikejiri
    First Department of Internal Medicine, Showa University School of Medicine, Tokkyo, Japan
    Metabolism 53:1113-7. 2004
    ..These results suggest that atorvastatin is safe and effective for the management of dyslipidemia in patients with CFR who are receiving HD, which may help to suppress the development of atherosclerosis...
  75. ncbi Serum levels of lipids and lipoproteins in Syrian patients with beta-thalassemia major
    Faizeh A Al-Quobaili
    Department of Biochemistry and Microbiology, Faculty of Pharmacy, Damascus University, PO Box 6735, Damascus, Syria
    Saudi Med J 25:871-5. 2004
    ..Evaluation serum lipids, lipoprotein (a), apolipoprotein A1, apolipoprotein B and total antioxidant status (TAS) in syrian patients with beta-thalassemia major...
  76. ncbi Antibodies against human oxidized low-density lipoprotein (LDL) as markers for human plasma modified lipoproteins
    Luminita Radulescu
    Institute of Cellular Biology and Pathology Nicolae Simionescu, Romanian Academy, Bucharest, Romania
    Med Sci Monit 10:BR207-14. 2004
    ..CONCLUSIONS: These antibodies can be considered as markers of the pathogenic determinants of atherosclerosis, such as enhanced lipid oxidation, pro-inflammatory stage, and impaired vasodilatation...
  77. ncbi Abnormalities in apolipoprotein and lipid levels in an HIV-infected Brazilian population under different treatment profiles: the relevance of apolipoprotein E genotypes and immunological status
    Iran Malavazi
    Institute of Chemistry, Faculty of Pharmaceutical Sciences, Sao Paulo State University UNESP, Araraquara, Brazil
    Clin Chem Lab Med 42:525-32. 2004
    ..Dyslipidemia was a predictable consequence of HIV infection and the protease inhibitors intensified the increase in apoE values...
  78. ncbi Transient remnant removal disease in acute fatty liver of pregnancy
    Birgit Wetzka
    Department of Obstetrics and Gynecology, University of Freiburg, Freiburg, Germany
    Hypertens Pregnancy 23:143-53. 2004
    ..As these triglyceride-rich particles cause endothelial dysfunction, they may contribute to the pathophysiology of AFLP...
  79. ncbi Regulation of plasma triglycerides in insulin resistance and diabetes
    Henry N Ginsberg
    College of Physicians and Surgeons of Columbia University, New York, NY 10032, USA
    Arch Med Res 36:232-40. 2005
    ....
  80. ncbi TRL, IDL, and LDL apolipoprotein B-100 and HDL apolipoprotein A-I kinetics as a function of age and menopausal status
    Nirupa R Matthan
    Cardiovascular Nutrition, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, 711 Washington St, Boston, MA 02111, USA
    Arterioscler Thromb Vasc Biol 25:1691-6. 2005
    ..To determine mechanisms contributing to the altered lipoprotein profile associated with aging and menopause, apolipoprotein B-100 (apoB-100) and apoA-I kinetic behavior was assessed...
  81. ncbi Plasma carboxyl ester lipase activity modulates apolipoprotein B-containing lipoprotein metabolism in a transgenic mouse model
    Ling Li
    Laboratory of Lipoprotein Research, Cardiovascular Institute, Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    Metabolism 57:1361-8. 2008
    ..In summary, our results demonstrate that plasma CEL modulates apo B-Lp metabolism in vivo, resulting in reduced VLDL clearance and elevated plasma cholesterol levels...
  82. ncbi Alterations in rat serum lipids and apolipoproteins following clofibrate treatment
    N Dashti
    Atherosclerosis 49:255-66. 1983
    ..These observations suggest that the hypolipidemic effect of clofibrate in the normolipemic rat is caused mainly by diminished hepatic secretion, rather than by enhanced catabolism, of triglyceride-rich lipoproteins...
  83. ncbi Decreased lipoprotein clearance is responsible for increased cholesterol in LDL receptor knockout mice with streptozotocin-induced diabetes
    Ira J Goldberg
    Division of Preventive Medicine, Columbia University, New York, New York 10032, USA
    Diabetes 57:1674-82. 2008
    ..Patients with diabetes often have dyslipidemia and increased postprandial lipidmia. Induction of diabetes in LDL receptor (Ldlr(-/-)) knockout mice also leads to marked dyslipidemia. The reasons for this are unclear...
  84. ncbi Resveratrol attenuates the expression of HMG-CoA reductase mRNA in hamsters
    Il Jin Cho
    Division of Food Function Research, Korea Food Research Institute, 46 1 Baekhyun Dong, Bundang gu, Songnam si, Kyunggi Do 463 746, Republic of Korea
    Biochem Biophys Res Commun 367:190-4. 2008
    ..These results indicate that dietary resveratrol reduces serum cholesterol by down-regulating hepatic HMGR mRNA expression in hamsters fed a high-fat diet...
  85. ncbi Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2
    Vasilios G Saougos
    Department of Internal Medicine, Medical School, University of Ioannina, 45110 Ioannina, Greece
    Arterioscler Thromb Vasc Biol 27:2236-43. 2007
    ..We investigated the effect of 3 hypolipidemic drugs that exert their action through different mechanisms on plasma and lipoprotein-associated Lp-PLA2 activity and mass...
  86. ncbi A mouse model with features of familial combined hyperlipidemia
    L Masucci-Magoulas
    Department of Medicine, Columbia University, 630 West 168 Street, New York, NY 10032, USA
    Science 275:391-4. 1997
    ..This mouse model may provide clues to the origin of human FCHL...
  87. ncbi Serum adiponectin levels, insulin resistance, and lipid profile in children born small for gestational age are affected by the severity of growth retardation at birth
    Eleni N Evagelidou
    Neonatal Intensive Care Unit, University of Ioannia, Greece
    Eur J Endocrinol 156:271-7. 2007
    ....
  88. ncbi Nine months aerobic fitness induced changes on blood lipids and lipoproteins in untrained subjects versus controls
    Susanne Ring Dimitriou
    Department of Sport Science and Kinesiology, University of Salzburg, Salzburg, Austria
    Eur J Appl Physiol 99:291-9. 2007
    ..04) compared to the control group (NS). In 9 months, E achieved 24% increase in VO(2peak) and 18% reduction in Apo B, denoting the impact of cardiovascular fitness on cardiovascular risk...
  89. ncbi Hypolipidaemic effect of chemically different mucilages in rats: a comparative study
    Puthenpura T Boban
    Department of Biochemistry, University of Kerala, Kariavattom Campus, Thiruvananthapuram, Kerala 695 581, India
    Br J Nutr 96:1021-9. 2006
    ..The present results suggested that the hypolipidaemic effect of dietary fibre involves a decrease in hepatic production of VLDL and further that it varies with the nature of the fibre...
  90. ncbi Effect of levo-thyroxine replacement on non-high-density lipoprotein cholesterol in hypothyroid patients
    Mitsuru Ito
    Kuma Hospital, Kobe 650 0011, Japan
    J Clin Endocrinol Metab 92:608-11. 2007
    ..Recently, non-high-density lipoprotein cholesterol (non-HDL-C), a measure of total cholesterol minus HDL-C, has emerged as a predictor of cardiovascular disease...
  91. ncbi Effect of dialysis type on serum lipids, apolipoproteins, and lipoproteins
    Mehmet Kanbay
    Department of Nephrology, Fatih University, Faculty of Medicine, Turkey
    Ren Fail 28:567-71. 2006
    ..The aim of this study was to determine the effect of dialysis type on serum lipid levels...
  92. ncbi Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels
    X C Jiang
    Division of Molecular Medicine, Department of Medicine, Columbia University, New York, New York 10032, USA
    J Clin Invest 103:907-14. 1999
    ..Vesicular lipoproteins accumulating in PLTP-/- mice on a high-fat diet could influence the development of atherosclerosis...
  93. ncbi Pharmacological characterization in vitro of EP2306 and EP2302, potent inhibitors of squalene synthase and lipid biosynthesis
    Anna Tavridou
    ELPEN Pharmaceutical Co Inc, 95 Marathonos Av, 19009 Pikermi, Greece
    Eur J Pharmacol 535:34-42. 2006
    ..These results suggest that EP2306 and EP2302 might prove to be useful for lipid-lowering and treatment of atherosclerosis in vivo...
  94. ncbi Saturated fat-induced changes in Sf 60-400 particle composition reduces uptake of LDL by HepG2 cells
    Kim G Jackson
    School of Food Biosciences, University of Reading, Reading, Berkshire, United Kingdom
    J Lipid Res 47:393-403. 2006
    ..008). In conclusion, these findings suggest an alternative or additional mechanism whereby acute fat ingestion can influence LDL clearance via competitive apoE-dependent effects of TRL on the LDL receptor...
  95. ncbi Lipoprotein-like particles and cholesteryl esters in human Bruch's membrane: initial characterization
    Chuan-Ming Li
    Department of Ophthalmology, University of Alabama School of Medicine, Birmingham, AL 35294-009, USA
    Invest Ophthalmol Vis Sci 46:2576-86. 2005
    ..Evidence of intraocular apoB and apoA-I expression supports an emerging hypothesis that the RPE assembles and secretes a large, possibly novel, lipoprotein particle...
  96. ncbi Characterisation of the lipoprotein structure in the St. Thomas' Mixed Hyperlipidaemic (SMHL) rabbit
    Baukje de Roos
    Department of Vascular Biochemistry, Division of Cardiovascular and Medical Sciences, Glasgow, UK
    Atherosclerosis 181:63-8. 2005
    ....
  97. ncbi Variable effects of different corticosteroids on plasma lipids, apolipoproteins, and hepatic apolipoprotein mRNA levels in rats
    B Staels
    Laboratorium voor Experimentele Geneeskunde en Endocrinologie, Gasthuisberg, Belgium
    Arterioscler Thromb 11:760-9. 1991
    ....
  98. ncbi [Relationship between the Nco I, Ava II polymorphism of low density lipoprotein receptor gene and atherosclerotic cerebral infarction]
    Yang Guo
    Department of Neurology, the Second Clinical College, China Medical University, Shenyang, Liaoning, 110004 P R China
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi 19:209-12. 2002
    ..29, 7.67, 9.33 and 3.09(P<0.05), respectively. CONCLUSION The coexistence of A(-) A(-) and N(+) N(+) can affect the concentration of lipid and lipoprotein and is in close relationship with the occurrence of ACI...
  99. ncbi Comparison of lipid and non-lipid markers of atherosclerosis in arterial versus venous blood
    Bruce Palmer
    Cardiac and Vascular Institute, Scott and White Memorial Hospital and Clinic, Scott, Sherwood and Brindley Foundation, The Texas A and M University System Health Science Center, College of Medicine, Temple, TX 76508, USA
    Ann Clin Biochem 40:286-8. 2003
    ..CONCLUSION: Arterial and venous blood can be used interchangeably to study the effect of blood concentrations of common soluble surrogate markers of atherosclerosis...
  100. ncbi Lipid composition and lipopolysaccharide binding capacity of lipoproteins in plasma and lymph of patients with systemic inflammatory response syndrome and multiple organ failure
    Johannes H M Levels
    Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
    Crit Care Med 31:1647-53. 2003
    ..Moreover, in plasma and lymph, novel cholesterol-containing particles, resembling high-density lipoprotein, were identified in the SIRS/MOF patient group...
  101. ncbi Plasma lipid composition and LDL oxidation
    Patrizia Brizzi
    Diabetes Service, Department of Medicine, University of Sassari, Italy
    Clin Chem Lab Med 41:56-60. 2003
    ..Both LDL/TG and LDL/HDL ratios can be used as predictive parameters of in vivo LDL oxidation...

Research Grants92

  1. Development of CNS-targeted AAV vectors
    Miguel Esteves; Fiscal Year: 2009
    ..The proposed studies benefit from unique features of the scientific environment, subject populations, or employ useful collaborative arrangements. There is evidence of institutional support. ..
  2. APOLIPOPROTEIN B48 AND LIPOPROTEIN METABOLISM
    Lawrence Chan; Fiscal Year: 2004
    ..Thus, the overall project is highly relevant to lipid nutrient absorption and homeostasis. Significantly, it also provides important information on a newly described pathway in posttranscriptional gene regulation. ..
  3. ASSEMBLY PATHWAY OF VLDL--A THREE STEP PROCESS
    LARRY SWIFT; Fiscal Year: 2001
    ..Specific methods are spelled out in much greater detail in a separate section on specific methods. Both the rat and the cell culture experiments are very well defined as is the proposed time table for the studies. ..
  4. ApoB and ApoA-I Kinetics in the ApoB-67 Mutation
    Francine Welty; Fiscal Year: 2006
    ..The apoB-67 mutation may provide insights into mechanisms of low LDL-C and high HDL-C levels and new and better therapies to lower cholesterol. ..
  5. REGULATION OF APOB SECRETION IN INBRED MOUSE STRAINS
    Li Shin Huang; Fiscal Year: 2009
    ..It will also be a potential target for drug discovery and pharmacological intervention in hyperlipidemic patients in the general population. ..
  6. INTESTINAL LIPOPROTEINS IN THE NEONATE
    Dennis Black; Fiscal Year: 2001
    ..Results of these studies will ultimately guide the provision of dietary lipid to the neonate in a form which will optimize lipoprotein and apolipoprotein synthesis and secretion. ..
  7. LIPOGENESIS & LIPOPROTEIN COMPLICATIONS OF HIV THERAPY
    David Hui; Fiscal Year: 2004
    ..Collaboration with the companion grant will facilitate the evaluation of dietary and/or therapeutic manipulations as treatment to suppress the adverse effects of PI. ..
  8. EDITING OF APOLIPOPROTEIN-B MRNA
    DONNA DRISCOLL; Fiscal Year: 2004
    ..The successful pursuit of these aims should provide insight into the mechanism of apo-B mRNA editing and the function of ACF. ..
  9. APOLIPOPROTEIN B48 AND LIPOPROTEIN METABOLISM
    Lawrence Chan; Fiscal Year: 1999
    ..The project may provide important information related to lipoprotein metabolism and atherosclerosis and a novel pathway involved in the posttranscriptional regulation of gene expression. ..
  10. METABOLISM AND GENETICS OF HYPOBETALIPOPROTEINEMIA
    Gustav Schonfeld; Fiscal Year: 2002
    ..In all these families it has been documented that the affected subjects do not have any evidence of truncated for of apoB. ..
  11. METABOLIC REGULATION OF APOLIPOPROTEIN B MRNA EDITING
    Harold Smith; Fiscal Year: 1999
    ..Through the proposed research, it should be possible to determine which proteins and interactions are necessary and sufficient for editing to occur, and which factors and interactions are involved in modulating the level of editing. ..
  12. EDITING OF APOLIPOPROTEIN-B MRNA
    DONNA DRISCOLL; Fiscal Year: 1999
    ..Other mRNA targets of the enzyme or its subunits will be identified using tissue-specific combinatorial RNA shape libraries. The results of our studies will provide insight into the mechanism of apo-B mRNA editing. ..
  13. ENTEROHEPATIC LIPID FLUX AND APOPROTEIN BIOSYNTHESIS.
    NICHOLAS DAVIDSON; Fiscal Year: 2007
    ..We will examine the hypothesis in the current application that there are other cytidine deaminases, related to apobec-1, with functions involving site-specific RNA interactions. ..
  14. ENTEROHEPATIC LIPID FLUX AND APOPROTEIN BIOSYNTHESIS
    NICHOLAS DAVIDSON; Fiscal Year: 1999
    ..Taken together, this approach should allow elucidation of the molecular mechanisms underlying this novel pathway for gene regulation in the mammalian small intestine. ..
  15. MECHANISM OF PI-RELATED DYSLIPIDEMIA AND ATHEROSCLEROSIS
    Daniel Rader; Fiscal Year: 2004
    ..These studies will provide novel insights into the mechanisms of PI-associated dyslipidemia and atherosclerosis. ..
  16. ENTEROHEPATIC LIPID FLUX AND APOPROTEIN BIOSYNTHESIS
    NICHOLAS DAVIDSON; Fiscal Year: 2010
    ....
  17. METABOLIC REGULATION OF APOLIPOPROTEIN B MRNA EDITING
    Harold Smith; Fiscal Year: 2003
    ....
  18. METABOLIC REGULATION OF APO B MRNA EDITING
    Harold Smith; Fiscal Year: 1993
    ..Moreover, the information obtained in these studies will be important for evaluating the generic properties of mRNA editing and identifying other mRNAs which might serve as editing substrates...